Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2021-10-01
2022-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* indications of use .
* proper dosage.
* proper management of side effects of their use.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Outcome of SVT in Children Admitted to AUCH
NCT07143591
Shortening Duration of Antiarrhythmic Medication for SVT in Infants
NCT04837261
Mobile Electrocardiogram Monitoring for Detecting Arrhythmias in Children
NCT05140343
Echo and ECG Findings in Neuropediatrics
NCT07184008
Atropine vs Isoprenaline in the Invasive Diagnosis of Arrhythmias
NCT06082388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
By altering the activity of these ion channels, the action potential is changed in an attempt to reduce the likelihood of sustained arrhythmias. There is awide range of antiarrhysmic drugs used in treatment Antiarrhysmics are therefore divided into five classes
Class I: Antiarrhythmics that affect sodium channels (slow depolarization) Class II: Drugs that counteract the sympathetic nervous system, predominantly beta-blockers Class III: drugs that affect the potasium channels ( prolong repolarization) Class IV: Drugs that affect calcium channels (Calcium channel blockers) Class V: Vagotonic drugs (Digoxin) and other miscellaneous drugs
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antiarrhythmic drug
all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Areej Tarek Mostafa mohamed makhlouf
Principle investegator , Areej Tarek Mostafa
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Podrid PJ. Antiarrhythmic drug selection. Annu Rev Med. 1987;38:1-17. doi: 10.1146/annurev.me.38.020187.000245.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
antiarrhythmic drugs in pediat
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.